Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  ACS Medicinal Chemistry Letters

• Publication date

  2018-02-13

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acsmedchemlett.8b00003PMID 29541371PMCID PMC5846130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.

  2016cited by this paper
• Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

  2014cited by this paper
• Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

  2013cited by this paper
• Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.

  2013cited by this paper
• PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.

  2013cited by this paper
• Abiraterone in Prostate Cancer: A New Angle to an Old Problem

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit

  2012cited by this paper
• MDV3100 for the treatment of prostate cancer

  2012cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Suppression of inflammation by a synthetic histone mimic

  2010cited by this paper
• Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

  2010cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• Synthesis by microwave irradiation of a substituted benzoxazine parallel library with preferential relaxant activity for guinea pig trachealis.

  2004cited by this paper
• Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Cancer statistics

  1989cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Binding Selectivity of Inhibitors to BRD2 Uncovered by Molecular Docking and Molecular Dynamics Simulations

  2025cites this paper
• A Modular Approach to Access 1,4-Benzoxazinones, Spirooxazolidinones, and 4,1-Benzoxazepinones via Oxidative Aryl C-N Bond Formation Using Catalytic Hypervalent Iodine.

  2025cites this paper
• New frontiers in prostate cancer treatment from systemic therapy to targeted therapy

  2025cites this paper
• Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors

  2025cites this paper
• Greener and sustainable fabrication of DNA/RNA base-pair conjugates by [CuO[HN(C2H5)3[Al2Cl7] nanocatalyst: Emerging drug against prostate cancer

  2024cites this paper
• Iron-Catalyzed Synthesis of Ferrocenyl–Thioether Conjugates via C–S Cross-Coupling of Thioethers and Vinylic Chlorides: Construction, Anticancer, and Computational Studies

  2024cites this paper
• Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation.

  2023cites this paper
• Theoretical evaluation of interaction of some dibenzo derivatives on both androgen receptor and 5α-reductase enzyme

  2022cites this paper
• From Therapy Resistance to Targeted Therapies in Prostate Cancer

  2022cites this paper
• Mechanistic Analysis of Chemically Diverse Bromodomain-4 Inhibitors Using Balanced QSAR Analysis and Supported by X-ray Resolved Crystal Structures

  2022cites this paper
• Evaluation of Interaction of Some Quinolone Derivatives on RSK-4 Using a Theoretical Model

  2022cites this paper
• Computational Evaluation of Dibenzo Compounds as Potential Dual Inhibitors of Androgen Receptor and 5α-Reductase

  2022cites this paper
• Theoretical Assessment of the Interaction Between Selected Quinolone Derivatives and RSK-4

  2022cites this paper
• The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.

  2021cites this paper
• Y06014 is a selective BET inhibitor for the treatment of prostate cancer

  2021cites this paper
• Synthesis, molecular structure, DFT studies, in silico docking and molecular dynamics simulations of 2,6 dimethoxychalcone derivatives as BRD4 inhibitors

  2021cites this paper
• Metal‐Free Twofold Electrochemical C−H Amination of Activated Arenes: Application to Medicinally Relevant Precursor Synthesis

  2020cites this paper
• Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.

  2019cites this paper
• BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK

  2019cites this paper
• BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor

  2019cites this paper
• Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain

  2018cites this paper
• Targeting Brd4 for cancer therapy: inhibitors and degraders.

  2018cites this paper